Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4103/0971-9784.159811 http://scihub22266oqcxt.onion/10.4103/0971-9784.159811 C4881725!4881725!26139748     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ann+Card+Anaesth 2015 ; 18 (3): 394-402 Nephropedia Template TP {{tp|p=26139748|t=2015. Inhaled therapy for the management of perioperative pulmonary hypertension |pdf=|usr=}}{{26139748}} gab.com Text Inhaled therapy for the management of perioperative pulmonary hypertension JO: Ann Card Anaesth http://www.kidney.de/pget.php?&tw=1&pmid=26139748 #FOAvip Patients with pulmonary hypertension (PH) are at high risk for complications in the perioperative setting and often receive vasodilators to control elevated pulmonary artery pressure (PAP). Administration of vasodilators via inhalation is an effective strategy for reducing PAP while avoiding systemic side effects, chiefly hypotension. The prototypical inhaled pulmonary-specific vasodilator, nitric oxide (NO), has a proven track record but is expensive and cumbersome to implement. Alternatives to NO, including prostanoids (such as epoprostenol, iloprost, and treprostinil), NO-donating drugs (sodium nitroprusside, nitroglycerin, and nitrite), and phosphodiesterase inhibitors (milrinone, sildenafil) may be given via inhalation for the purpose of treating elevated PAP. This review will focus on the perioperative therapy of PH using inhaled vasodilators. Twit Text FOAVip Inhaled therapy for the management of perioperative pulmonary hypertension ????Ann Card Anaesth http://www.kidney.de/pget.php?&tw=1&pmid=26139748 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26139748 #FOAvip English Wikipedia <ref>{{Cite pmid|26139748}}</ref> Inhaled therapy for the management of perioperative pulmonary hypertension #MMPMID26139748 Thunberg CA; Morozowich ST; Ramakrishna H Ann Card Anaesth 2015[Jul]; 18 (3): 394-402 PMID26139748show ga Patients with pulmonary hypertension (PH) are at high risk for complications in the perioperative setting and often receive vasodilators to control elevated pulmonary artery pressure (PAP). Administration of vasodilators via inhalation is an effective strategy for reducing PAP while avoiding systemic side effects, chiefly hypotension. The prototypical inhaled pulmonary-specific vasodilator, nitric oxide (NO), has a proven track record but is expensive and cumbersome to implement. Alternatives to NO, including prostanoids (such as epoprostenol, iloprost, and treprostinil), NO-donating drugs (sodium nitroprusside, nitroglycerin, and nitrite), and phosphodiesterase inhibitors (milrinone, sildenafil) may be given via inhalation for the purpose of treating elevated PAP. This review will focus on the perioperative therapy of PH using inhaled vasodilators. äInhaled therapy for the management of perioperative pulmonary hyperten(epmc).pdf DeepDyve Pubget Overpricing